The earliest clinical application for this new tool was as a putative therapy for HIV infection in which cytolytic CD8+ T cells (CTLs) were genetically modified to express natural HIV ligand CD4 as an extracellular domain, along with a transmembrane domain and a signal transducing intracellular domain CD3ζ [24]. The gene discussed is CD4; the disease is HIV infectious disease.